A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression

NCT04970693 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
Oligoprogressive

Interventions

DRUG: Furmonertinib

Sponsor

Sun Yat-sen University